International Clinical Trial: A post-licensing clinical evaluation of the efficacy, safety and tolerability of WT-1 Trastuzumab biosimilar in clinical practice for metastatic HER2-positive breast cancer

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (TCTR20260724003) titled 'A post-licensing clinical evaluation of the efficacy, safety and tolerability of WT-1 Trastuzumab biosimilar in clinical practice for metastatic HER2-positive breast cancer' on July 24.

Study Type: Interventional

Study Design: N/A

Primary Sponsor: Chulabhorn Foundation by Chulabhorn Research Institute

Condition: Women aged 18 to 75 years with HER2-positive metastatic breast cancer Biosimilar, efficacy, safety, trastuzumab, Real-world, metastatic breast cancer, HER2-positive Biosimilar, efficacy, safety, trastuzumab, Real-world, metastatic breast cancer, HER2-positive

Intervention: Participants will receive ...